Evidence map›Paper›PMID 36671630›Full record

ReviewBioengineering (Basel, Switzerland)2023

Evolution and Clinical Advances of Platelet-Rich Fibrin in Musculoskeletal Regeneration.

Ragunanthan Narayanaswamy, Bishnu Prasad Patro, Naveen Jeyaraman, Prakash Gangadaran, Ramya Lakshmi Rajendran, Arulkumar Nallakumarasamy, Madhan Jeyaraman, Prasanna Ramani, Byeong-Cheol Ahn

Abstract readReview
In one paragraph

Review in Bioengineering (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ragunanthan NarayanaswamyDepartment of Orthopaedics, Rathimed Speciality Hospital, Chennai 600040, India.
Bishnu Prasad PatroDepartment of Orthopaedics, All India Institute of Medical Sciences, Bhubaneswar 751019, India.ORCID 0000-0001-9497-9624
Naveen JeyaramanDepartment of Orthopaedics, Rathimed Speciality Hospital, Chennai 600040, India.ORCID 0000-0002-4362-3326
Prakash GangadaranDepartment of Nuclear Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu 41944, Republic of Korea.ORCID 0000-0002-0658-4604
Ramya Lakshmi RajendranDepartment of Nuclear Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu 41944, Republic of Korea.ORCID 0000-0001-6987-0854
Arulkumar NallakumarasamyDepartment of Orthopaedics, All India Institute of Medical Sciences, Bhubaneswar 751019, India.ORCID 0000-0002-2445-2883
Madhan JeyaramanDepartment of Orthopaedics, Rathimed Speciality Hospital, Chennai 600040, India.ORCID 0000-0002-9045-9493
Prasanna RamaniDhanvanthri Laboratory, Department of Sciences, Amrita School of Physical Sciences, Amrita Vishwa Vidyapeetham, Coimbatore 641112, India.ORCID 0000-0002-5236-7141
Byeong-Cheol AhnDepartment of Nuclear Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu 41944, Republic of Korea.ORCID 0000-0001-7700-3929

Funding

National Research Foundation of Korea NRF-2021R1I1A1A01040732National Research Foundation of Korea NRF-2022R1I1A1A01068652
6 · The paper itself

Abstract

Over the past few decades, various forms of platelet concentrates have evolved with significant clinical utility. The newer generation products, including leukocyte-platelet-rich fibrin (L-PRF) and advanced platelet-rich fibrin (A-PRF), have shown superior biological properties in musculoskeletal regeneration than the first-generation concentrates, such as platelet-rich plasma (PRP) and plasma rich in growth factors. These newer platelet concentrates have a complete matrix of physiological fibrin that acts as a scaffold with a three-dimensional (3D) architecture. Further, it facilitates intercellular signaling and migration, thereby promoting angiogenic, chondrogenic, and osteogenic activities. A-PRF with higher leukocyte inclusion possesses antimicrobial activity than the first generations. Due to the presence of enormous amounts of growth factors and anti-inflammatory cytokines that are released, A-PRF has the potential to replicate the various physiological and immunological factors of wound healing. In addition, there are more neutrophils, monocytes, and macrophages, all of which secrete essential chemotactic molecules. As a result, both L-PRF and A-PRF are used in the management of musculoskeletal conditions, such as chondral injuries, tendinopathies, tissue regeneration, and other sports-related injuries. In addition to this, its applications have been expanded to include the fields of reconstructive cosmetic surgery, wound healing in diabetic patients, and maxillofacial surgeries.

Indexed as

cytokinesgrowth factorsintercellular signalingplatelet-rich fibrin

Identifiers

PMID36671630
PMCPMC9854731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.